Trials / Not Yet Recruiting
Not Yet RecruitingNCT04883918
ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Evaluation of Safety and Efficacy of ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- ASC Therapeutics · Industry
- Sex
- All
- Age
- 2 Months
- Healthy volunteers
- Not accepted
Summary
Acute GVHD following allogeneic HCT is an immune-triggered process, leading to profound immune dysregulation and organ dysfunction. Despite pivotal advances, aGVHD is one of the leading causes of non-relapse mortality in patients undergoing HCT. Placenta-derived DSCs, isolated from the fetal membrane of maternal origin, are a type of stromal cells with well-characterized immunosuppressive properties. The current study is designed to assess the safety and efficacy of 4 intravenous (IV) doses of ASC930 DSC cells in aGVHD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ASC930 | 4 intravenous doses of ASC930 |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2026-01-01
- Completion
- 2026-04-01
- First posted
- 2021-05-12
- Last updated
- 2023-07-20
Source: ClinicalTrials.gov record NCT04883918. Inclusion in this directory is not an endorsement.